{"id":"W4399452369","doi":"10.1200/jco.2024.42.17_suppl.lba7005","title":"Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; Queen Elizabeth II Health Sciences Centre; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Lenalidomide; Internal medicine; Brentuximab vedotin; Rituximab; Population; Oncology; Refractory (planetary science); Clinical endpoint; Placebo; Phases of clinical research; Diffuse large B-cell lymphoma; Interim analysis; Gastroenterology; Surgery; Lymphoma; CD30; Chemotherapy; Randomized controlled trial; Multiple myeloma; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002396042,0.001080031,0.00203563,0.0003783067,0.0002551407,0.001109625,0.0009119253,0.0009544025,0.001484304],"category_scores_gemma":[0.001030993,0.0004955268,0.00158315,0.0004663219,0.0006526703,0.0009261646,0.0003922838,0.002081328,0.0005043593],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001128181,"about_ca_system_score_gemma":0.001092035,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001315167,"about_ca_topic_score_gemma":0.003276847,"domain_scores_codex":[0.9993112,0.0004039752,0.00003957411,0.00007788701,0.00007300866,0.00009433545],"domain_scores_gemma":[0.9993678,0.0001237625,0.0001661653,0.00004989778,0.00003239543,0.0002599968],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8255762,0.02106577,0.02150597,0.0008683054,0.004791881,0.0002470999,0.0002287461,0.002354407,0.01470482,0.0001485738,0.00359807,0.1049102],"study_design_scores_gemma":[0.6865453,0.2433584,0.05757252,0.0001045444,0.003076662,0.0004348888,0.0001253482,0.002031048,0.001853273,0.0002644936,0.004586209,0.00004741787],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9898201,0.006703234,0.0002965541,0.0003706436,0.0000957456,0.0006073336,0.0008740243,0.00005861313,0.001173748],"genre_scores_gemma":[0.9929218,0.002178273,0.0006887458,0.0007428803,0.0001441926,0.0005536683,0.001923843,0.0000214318,0.0008252825],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002396042,"threshold_uncertainty_score":0.01267165,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05589310246874222,"score_gpt":0.4174722031736733,"score_spread":0.3615791007049311,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}